2020
A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.
Shapira R, Weber J, Geva R, Sznol M, Kluger H, Wong D, Liang B. A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies. Journal Of Clinical Oncology 2020, 38: 3094-3094. DOI: 10.1200/jco.2020.38.15_suppl.3094.Peer-Reviewed Original ResearchWeek regimenCEACAM1 expressionAnti-PD-1 therapyPhase 1/2 clinical trialCell adhesion molecule-1Drug-related AEsHigh CEACAM1 expressionPhase 2 doseSingle-dose escalationMedian overall survivalAnti-tumor responseMulti-dose studyBest overall responseAdhesion molecule-1Poor disease prognosisExhausted lymphocytesStable diseaseSevere AEsAdult patientsOverall survivalTim-3Frequent AEsImmune checkpointsRecurrent malignancyRecurrent cancer
2017
Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
Sharma A, Vatapalli R, Abdelfatah E, McMahon K, Kerner Z, Guzzetta A, Singh J, Zahnow C, Baylin S, Yerram S, Hu Y, Azad N, Ahuja N. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. PLOS ONE 2017, 12: e0176139. PMID: 28445481, PMCID: PMC5405959, DOI: 10.1371/journal.pone.0176139.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsATP-Binding Cassette TransportersAzacitidineCaco-2 CellsCamptothecinCell AdhesionCell Line, TumorCell ProliferationColorectal NeoplasmsDNA MethylationDNA RepairGene ExpressionGene Expression ProfilingHCT116 CellsHumansIrinotecanLong Interspersed Nucleotide ElementsMiceMice, Inbred NODMice, SCIDConceptsCRC cell linesColorectal cancerMultiple CRC cell linesPhase 1/2 clinical trialCell linesMetastatic colorectal cancerMajority of patientsNOD-SCID miceColorectal cancer cellsSoft agar assayInitial therapyMetastatic settingCytotoxic chemotherapyCRC treatmentClinical efficacyCancer deathTumor regressionClinical trialsDNA demethylating agentVivo xenograftsChemotherapeutic agentsCancer cellsHCT116 cell linesAgar assayChemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply